Iterum Therapeutics PLC (NASDAQ:ITRM) shares are trending Tuesday after the company announced its Phase 3 Reassure trial met the primary endpoint of non-inferiority to Augmentin. The Details: Iterum Therapeutics announced positive topline results from its REASSURE (REnewed ASsessment of Sulopenem in uUTI caused by Resistant Enterobacterales) Phase 3 clinical trial comparing oral sulopenem (sulopenem etzadroxil combined with probenecid in a bilayer tablet) to oral Augmentin. “We are very pleased to announce positive data from this confirmatory trial, which was conducted under special protocol a…